# Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

> **NCT01312857** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 75 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** panitumumab
- **DRUG:** Randomization to No Panitumumab

## Key facts

- **NCT ID:** NCT01312857
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-07
- **Primary completion:** 2024-07-15
- **Final completion:** 2024-07-15
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01312857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01312857, "Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01312857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*